Literature DB >> 24096994

GH secretion reserve in subclinical hypercortisolism.

Serena Palmieri1, Valentina Morelli, Antonio Stefano Salcuni, Cristina Eller-Vainicher, Elisa Cairoli, Volha V Zhukouskaya, Paolo Beck-Peccoz, Alfredo Scillitani, Iacopo Chiodini.   

Abstract

PURPOSE: In overt hypercortisolism, growth hormone (GH) secretion is decreased and normalizes after surgery. In subclinical hypercortisolism (SH), GH secretion has been scarcely investigated. We assessed GH reserve in patients with and without SH and, in the former, also after recovery.
METHODS: We enrolled 24 patients with adrenal adenomas, 12 with SH (SH+, 8 females, 58.3 ± 6.5 years) and 12 without SH (SH-; 11 females, 61.8 ± 10.6 years). SH was diagnosed in the presence of ≥ 2 out of: 1 mg overnight dexamethasone suppression test >83 nmol/L, urinary free cortisol (UFC) >193 nmol/day and ACTH levels <2.2 pmol/L. GH secretion was assessed by GHRH + Arginine test (GHRH-ARG) and age-adjusted serum IGF-I levels, expressed as SDS (IGF-I SDS). Eight SH+ patients were re-evaluated after the recovery from SH.
RESULTS: Age, gender, body mass index (BMI) and IGF-I SDS were comparable between SH+ and SH- patients. After GHRH-ARG the mean GH peak levels (GH-P) and GH response (as Area Under Curve, GH-AUC) were lower in SH+ than in SH- patients (15.2 ± 8.1 vs 44.5 ± 30.9 μg/L, P = 0.004 and 1,418 ± 803 vs 4,028 ± 2,476 μg/L/120 min, P = 0.002, respectively), after adjusting for age and BMI. The GH-AUC and GH-P levels were negatively associated with UFC after adjusting for age and BMI (β = -0.39, P = 0.02 and β = -0.4, P = 0.020 respectively). After recovery, GH-P levels and GH-AUC increased as compared to baseline (23.7 ± 16.3 vs 15.8 ± 10.2 μg/L, P = 0.036 and 2,549 ± 1,982 vs 1,618 ± 911 μg/L/120 min, P = 0.012, respectively).
CONCLUSIONS: GH secretion reserve is decreased in SH patients and increases after the recovery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24096994     DOI: 10.1007/s11102-013-0528-7

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  25 in total

Review 1.  Cushing's syndrome.

Authors:  M Boscaro; L Barzon; F Fallo; N Sonino
Journal:  Lancet       Date:  2001-03-10       Impact factor: 79.321

2.  Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.

Authors:  Alfonso Leal-Cerro; Alfonso Soto; Maria Asunción Martínez; Paula Alvarez; Luisa Isidro; Felipe F Casanueva; Carlos Dieguez; Fernando Cordido
Journal:  Clin Endocrinol (Oxf)       Date:  2002-12       Impact factor: 3.478

3.  Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients.

Authors:  Iacopo Chiodini; Massimo Torlontano; Alfredo Scillitani; Maura Arosio; Simonetta Bacci; Sergio Di Lembo; Paolo Epaminonda; Giovanni Augello; Riccardo Enrini; Bruno Ambrosi; Guido Adda; Vincenzo Trischitta
Journal:  Eur J Endocrinol       Date:  2005-12       Impact factor: 6.664

Review 4.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

Authors:  A Giustina; J D Veldhuis
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

5.  Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline.

Authors:  Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Mary Lee Vance
Journal:  J Clin Endocrinol Metab       Date:  2011-06       Impact factor: 5.958

6.  Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism.

Authors:  Iacopo Chiodini; Valentina Morelli; Antonio Stefano Salcuni; Cristina Eller-Vainicher; Massimo Torlontano; Francesca Coletti; Laura Iorio; Antonello Cuttitta; Angelo Ambrosio; Leonardo Vicentini; Fabio Pellegrini; Massimiliano Copetti; Paolo Beck-Peccoz; Maura Arosio; Bruno Ambrosi; Vincenzo Trischitta; Alfredo Scillitani
Journal:  J Clin Endocrinol Metab       Date:  2010-04-07       Impact factor: 5.958

7.  Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome.

Authors:  Marinella Tzanela; Niki Karavitaki; Christiana Stylianidou; Stylianos Tsagarakis; Nikos C Thalassinos
Journal:  Clin Endocrinol (Oxf)       Date:  2004-03       Impact factor: 3.478

Review 8.  NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma").

Authors: 
Journal:  NIH Consens State Sci Statements       Date:  2002 Feb 4-6

9.  Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies.

Authors:  W B Wehrenberg; P J Bergman; L Stagg; J Ndon; A Giustina
Journal:  Endocrinology       Date:  1990-12       Impact factor: 4.736

10.  Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study.

Authors:  Iacopo Chiodini; Valentina Morelli; Benedetta Masserini; Antonio Stefano Salcuni; Cristina Eller-Vainicher; Raffaella Viti; Francesca Coletti; Giuseppe Guglielmi; Claudia Battista; Vincenzo Carnevale; Laura Iorio; Paolo Beck-Peccoz; Maura Arosio; Bruno Ambrosi; Alfredo Scillitani
Journal:  J Clin Endocrinol Metab       Date:  2009-06-23       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.